CAR T-Cell Therapy Market Trends, Share, Demand, Competition, Revenue and Future Outlook
CAR T-Cell Therapy Market Growth, Size, Trends Analysis- By Drug Type, By Indication, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033
| Published: Oct-2024 | Report ID: PHAR2414 | Pages: 1 - 237 | Formats*: |
| Category : Pharmaceutical | |||
Global CAR T-Cell Therapy Market Introduction and Overview
According to SPER Market Research, the Global CAR T-Cell Therapy Market is estimated to reach USD 46.23 billion by 2033 with a CAGR of 28.78%.
The report includes an in-depth analysis of the Global CAR T-Cell Therapy Market, including market size and trends, product mix, applications, and supplier analysis. One of the most innovative methods for treating cancer is CAR T-cell therapy. This cutting-edge immunotherapy fights cancer by utilizing the patient's immune system. Certain hematologic malignancies, including some types of leukemia and lymphoma, have reacted remarkably well to CAR T-cell therapy, indicating its potential as a game-changing therapeutic alternative for patients who have not responded to traditional treatments.
- The US FDA gave BREYANZI (lisocabtagene maraleucel) expedited approval in May 2024 to treat adult patients with relapsed or refractory Follicular Lymphoma (FL) who have had two or more lines of systemic therapy in the past.
- The US FDA approved Gilead's modification of the YESCARTA (axicabtagene ciloleucel) manufacturing procedures in January 2023, lowering the median turnaround time (TAT) in the US from 16 days to 14 days.
Market Opportunities and Challenges
Opportunities- An important factor driving the market expansion for CAR T-cell treatment is the rise in leukemia prevalence. The incidence of leukemia, which is defined by the unchecked growth of aberrant white blood cells, has significantly increased in recent years. For example, the American Cancer Society estimates that over 60,650 new cases of leukemia were diagnosed in the United States in 2022. Numerous causes, such as lifestyle modifications, environmental exposures, and genetic predispositions, can be blamed for this increase A major opportunity for market growth and therapeutic breakthroughs is presented by the CAR T-cell therapy market's expansion into solid tumors. CAR T-cell treatments have historically been effective in treating hematopoietic cancers such B-cell lymphomas and acute lymphoblastic
Challenges- In the market for CAR T-cell therapy, finding patients for clinical trials is a major problem that can impede the creation and approval of new treatments. Enrolling enough patients is challenging due to the intricacy of CAR T-cell therapy trials, strict eligibility requirements, and the scarcity of target indications. The strict eligibility requirements for CAR T-cell trials are one of the main obstacles. The pool of eligible individuals is greatly reduced by these requirements, which frequently include particular genetic markers, illness subtypes, and prior treatment histories. Furthermore, patient recruitment is made more difficult by the geographical dispersion of individuals with uncommon malignancies. Rare diseases with a small patient base dispersed over huge geographic areas include relapsed large B-cell lymphoma and several forms of acute lymphoblastic leukemia (ALL).
Market Competitive Landscape
The Global CAR T-Cell Therapy Market is highly consolidated. Some of the market key players are Autolus Therapeutics, Bluebird Bio, Inc., Bristol-Myers Squibb, Caribou Biosciences, Inc., Cellectis, Celgene Corporation, Celyad Oncology, Cartesian Therapeutics, Inc., Gilead Sciences, Inc. (Kite Pharma Inc.), Intellia Therapeutics, Juno Therapeutics, Inc., Merck & Co., Inc., Miltenyi Biotech, Novartis AG, Pfizer, Inc.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Drug Type, By Indication, By End User |
| Regions covered | North America, Asia-Pacific, Latin America, Middle East & Africa and Europe |
| Companies Covered | Autolus Therapeutics, Bluebird Bio, Inc., Bristol-Myers Squibb, Caribou Biosciences, Inc., Cellectis, Celgene Corporation, Celyad Oncology, Cartesian Therapeutics, Inc., Gilead Sciences, Inc. (Kite Pharma Inc.), Intellia Therapeutics, Juno Therapeutics, Inc., Merck & Co., Inc., Miltenyi Biotech, Novartis AG, Pfizer, Inc. |
COVID-19 Impact on Global CAR T-Cell Therapy Market
Growth for CAR-T cell treatment slowed in 2020 as a result of the COVID-19 pandemic. The poor diagnostic rate of blood cancer during the pandemic was mostly caused by a number of issues that caused problems for the healthcare system. Furthermore, the pandemic caused supply chain disruptions, making it challenging for medical professionals to get the instruments and supplies needed to diagnose blood cancer, including imaging devices and blood tests. Furthermore, the diagnosis was made more difficult by the parallels between COVID-19 symptoms including fever, shortness of breath, and exhaustion and blood cancer. People had trouble identifying the necessity for blood cancer diagnostic testing because of these overlapping symptoms, which caused additional delays in diagnosis.
Key Target Audience:
- Healthcare Providers
- Patients and Caregivers
- Pharmaceutical and Biotechnology Companies
- Research Institutions and Academic Organizations
- Investors and Financial Analysts
- Regulatory Agencies
- Health Insurance Providers
- Medical Equipment Manufacturers
Our in-depth analysis of the Global CAR T-Cell Therapy Market includes the following segments:
| By Drug Type: | |
| By Indication: | |
| By End User: |
Key Topics Covered in the Report:
- Global CAR T-Cell Therapy Market Size (FY’2024-FY’2033)
- Overview of Global CAR T-Cell Therapy Market
- Segmentation of Global CAR T-Cell Therapy Market By Drug Type (Axicabtage Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Others)
- Segmentation of Global CAR T-Cell Therapy Market By Indication (Lymphoma, Acute Lymphocytic Leukemia, Others)
- Segmentation of Global CAR T-Cell Therapy Market By End User (Hospitals, Cancer Treatment Centers)
- Statistical Snap of Global CAR T-Cell Therapy Market
- Expansion Analysis of Global CAR T-Cell Therapy Market
- Problems and Obstacles in Global CAR T-Cell Therapy Market
- Competitive Landscape in the Global CAR T-Cell Therapy Market
- Impact of COVID-19 and Demonetization on Global CAR T-Cell Therapy Market
- Details on Current Investment in Global CAR T-Cell Therapy Market
- Competitive Analysis of Global CAR T-Cell Therapy Market
- Prominent Players in the Global CAR T-Cell Therapy Market
- SWOT Analysis of Global CAR T-Cell Therapy Market
- Global CAR T-Cell Therapy Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report1.2. Market segment analysis
2. Research Methodology
2.1. Research data source2.1.1. Secondary Data2.1.2. Primary Data2.1.3. SPER’s internal database2.1.4. Premium insight from KOL’s2.2. Market size estimation2.2.1. Top-down and Bottom-up approach2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis4.1.1. Drivers4.1.2. Restraints4.1.3. Opportunities4.1.4. Challenges4.2. COVID-19 Impacts of the Global CAR T-Cell Therapy Market.
5. Market variable and outlook
5.1. SWOT Analysis5.1.1. Strengths5.1.2. Weaknesses5.1.3. Opportunities5.1.4. Threats5.2. PESTEL Analysis5.2.1. Political Landscape5.2.2. Economic Landscape5.2.3. Social Landscape5.2.4. Technological Landscape5.2.5. Environmental Landscape5.2.6. Legal Landscape5.3. PORTER’s Five Forces5.3.1. Bargaining power of suppliers5.3.2. Bargaining power of buyers5.3.3. Threat of Substitute5.3.4. Threat of new entrant5.3.5. Competitive rivalry5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global CAR T-Cell Therapy Market Manufacturing Base Distribution, Sales Area, Product Type6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global CAR T-Cell Therapy Market
7. Global CAR T-Cell Therapy Market, By Drug Type (USD Million) 2020-2033
7.1. Global CAR T-Cell Therapy Market Size, Share and Forecast, By Drug Type, 2020-20267.2. Global CAR T-Cell Therapy Market Size, Share and Forecast, By Drug Type, 2027-20337.3. Axicabtagene Ciloleucel7.4. Tisagenlecleucel7.5. Brexucabtagene Autoleucel7.6. Others
8. Global CAR T-Cell Therapy Market, By Indication (USD Million) 2020-2033
8.1. Global CAR T-Cell Therapy Market Size, Share and Forecast, By Indication, 2020-20268.2. Global CAR T-Cell Therapy Market Size, Share and Forecast, By Indication, 2027-20338.3. Lymphoma8.4. Acute Lymphocytic Leukemia8.5. Others
9. Global CAR T-Cell Therapy Market, By End User (USD Million) 2020-2033
9.1. Global CAR T-Cell Therapy Market Size, Share and Forecast, By End User, 2020-20269.2. Global CAR T-Cell Therapy Market Size, Share and Forecast, By End User, 2027-20339.3. Hospitals9.4. Cancer Treatment Centers
10. Global CAR T-Cell Therapy Market Forecast, 2020-2033 (USD Million)
10.1. Global CAR T-Cell Therapy Market Size and Market Share
11. Global CAR T-Cell Therapy Market, By Region, 2020-2033 (USD Million)
11.1. Global CAR T-Cell Therapy Market Size and Market Share By Region (2020-2026)11.2. Global CAR T-Cell Therapy Market Size and Market Share By Region (2027-2033)11.3. Asia-Pacific11.3.1. Australia11.3.2. China11.3.3. India11.3.4. Japan11.3.5. South Korea11.3.6. Rest of Asia-Pacific11.4. Europe11.4.1. France11.4.2. Germany11.4.3. Italy11.4.4. Spain11.4.5. United Kingdom11.4.6. Rest of Europe11.5. Middle East and Africa11.5.1. Kingdom of Saudi Arabia11.5.2. United Arab Emirates11.5.3. Qatar11.5.4. South Africa11.5.5. Egypt11.5.6. Morocco11.5.7. Nigeria11.5.8. Rest of Middle-East and Africa11.6. North America11.6.1. Canada11.6.2. Mexico11.6.3. United States11.7. Latin America11.7.1. Argentina11.7.2. Brazil11.7.3. Rest of Latin America
12. Company Profile
12.1. Autolus Therapeutics12.1.1. Company details12.1.2. Financial outlook12.1.3. Product summary12.1.4. Recent developments12.2. Bluebird Bio, Inc.12.2.1. Company details12.2.2. Financial outlook12.2.3. Product summary12.2.4. Recent developments12.3. Bristol-Myers Squibb12.3.1. Company details12.3.2. Financial outlook12.3.3. Product summary12.3.4. Recent developments12.4. Caribou Biosciences, Inc.12.4.1. Company details12.4.2. Financial outlook12.4.3. Product summary12.4.4. Recent developments12.5. Cellectis12.5.1. Company details12.5.2. Financial outlook12.5.3. Product summary12.5.4. Recent developments12.6. Celgene Corporation12.6.1. Company details12.6.2. Financial outlook12.6.3. Product summary12.6.4. Recent developments12.7. Celyad Oncology12.7.1. Company details12.7.2. Financial outlook12.7.3. Product summary12.7.4. Recent developments12.8. Cartesian Therapeutics, Inc.12.8.1. Company details12.8.2. Financial outlook12.8.3. Product summary12.8.4. Recent developments12.9. Gilead Sciences, Inc. (Kite Pharma Inc.)12.9.1. Company details12.9.2. Financial outlook12.9.3. Product summary12.9.4. Recent developments12.10. Intellia Therapeutics12.10.1. Company details12.10.2. Financial outlook12.10.3. Product summary12.10.4. Recent developments12.11. Juno Therapeutics, Inc.12.11.1. Company details12.11.2. Financial outlook12.11.3. Product summary12.11.4. Recent developments12.12. Merck & Co., Inc.12.12.1. Company details12.12.2. Financial outlook12.12.3. Product summary12.12.4. Recent developments12.13. Miltenyi Biotech12.13.1. Company details12.13.2. Financial outlook12.13.3. Product summary12.13.4. Recent developments12.14. Novartis AG12.14.1. Company details12.14.2. Financial outlook12.14.3. Product summary12.14.4. Recent developments12.15. Pfizer, Inc.12.15.1. Company details12.15.2. Financial outlook12.15.3. Product summary12.15.4. Recent developments12.16. Others
13. Conclusion
14. List of Abbreviations
15. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
CAR T-Cell Therapy Market is projected to reach USD 46.23 billion by 2033, growing at a CAGR of 28.78% during the forecast period.
CAR T-Cell Therapy Market grew in Market size from 2024. The Market is expected to reach USD 46.23 billion by 2033, at a CAGR of 28.78% during the forecast period.
CAR T-Cell Therapy Market CAGR of 28.78% during the forecast period.
You can get the sample pages by clicking the link - Click Here
CAR T-Cell Therapy Market size is USD 46.23 billion from 2024 to 2033.
CAR T-Cell Therapy Market is covered By Drug Type, By Indication and By End User
The North America is anticipated to have the highest Market share in the CAR T-Cell Therapy Market.
The Key players in the Market include Companies Covered Autolus Therapeutics, Bluebird Bio, Inc., Bristol-Myers Squibb, Caribou Biosciences, Inc., Cellectis, Celgene Corporation, Celyad Oncology, Cartesian Therapeutics, Inc., Gilead Sciences, Inc. (Kite Pharma Inc.), Intellia Therapeutics, Juno Therapeutics, Inc., Merck & Co., Inc., Miltenyi Biotech, Novartis AG, Pfizer, Inc.
The high cost of advanced diabetes drugs and the financial burden of treating diabetes remain major obstacles to market growth, despite the fact that numerous drugs have been approved for the condition and that governments and industry players are launching numerous initiatives.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
